Skip to main content
Top
Published in: Digestive Diseases and Sciences 6/2021

01-06-2021 | Ultrasound | Original Article

High-Risk Characteristics Associated with Advanced Pancreatic Cystic Lesions: Results from a Retrospective Surgical Cohort

Authors: Liqi Sun, Wei Wang, Huiyun Zhu, Fei Jiang, Lisi Peng, Gang Jin, Zhendong Jin

Published in: Digestive Diseases and Sciences | Issue 6/2021

Login to get access

Abstract

Background and Aim

The management of pancreatic cystic lesions (PCLs) remains controversial. We performed a retrospective study to determine characteristics associated with advanced PCLs (A-PCLs) and whether these characteristics vary in different pathological types of PCLs. The additional diagnostic value of endoscopic ultrasound (EUS) was also evaluated.

Methods

Patients who underwent surgical resection for an identified PCLs by imaging modalities were included. A logistic regression model was developed to identify significant characteristics for A-PCLs. EUS data was assessed separately.

Results

Three hundred and fifty-three patients were included, and 125 patients (35.4%) were A-PCLs. The presence of main pancreatic duct (MPD) diameter ≥ 10 mm (odds ratio [OR], 11.7; 95% confidence interval [CI], 1.53–89.2; P = 0.018), mural nodules ≥ 5 mm (OR, 11.67; 95% CI, 2.3–59.05; P = 0.003), solid components within cysts (OR, 30.87; 95% CI, 7.23–131.7; P < 0.0001) and high serum CA19-9 levels (OR, 1.006; 95% CI, 1.001–1.011; P = 0.02) were independently associated with the presence of A-PCLs. The presence of septa was independently associated with the presence of non-A-PCLs (OR, 0.147; 95% CI, 0.04–0.6; P = 0.008). Males who had a history of tobacco abuse (P < 0.0001) and had a greatly dilated MPD (P < 0.0001) were more common in advanced intraductal papillary mucinous neoplasms (IPMC) patients. Solid pseudopapillary neoplasm (SPT) often occurred in young women (P < 0.0001), mostly asymptomatically (P < 0.0001) and with lower serum CA19-9 levels (P < 0.0001). In the 124 patients who underwent EUS-guided fine-needle aspiration (EUS-FNA), five additional characteristics (4 mural nodules and 1 MPD involvement) were identified by EUS imaging and 17 patients were identified with abnormal cytological results (13 atypical cells and 4 suspicious for malignancy cells) by EUS-FNA.

Conclusion

On the basis of a retrospective study with large sample size, the presence of MPD ≥ 10 mm, mural nodules, solid components, and high serum CA19-9 levels were independently associated with the presence of A-PCLs. The high-risk characteristics may vary across different types of A-PCLs. EUS and EUS-FNA could provide additional diagnostic information for PCLs.
Literature
1.
go back to reference Sun L, Wang Y, Jiang F, et al. Prevalence of pancreatic cystic lesions detected by magnetic resonance imaging in the Chinese population. J Gastroenterol Hepatol. 2019;34:1656–1662.CrossRef Sun L, Wang Y, Jiang F, et al. Prevalence of pancreatic cystic lesions detected by magnetic resonance imaging in the Chinese population. J Gastroenterol Hepatol. 2019;34:1656–1662.CrossRef
2.
go back to reference Zerboni G, Signoretti M, Crippa S, et al. Systematic review and meta-analysis: prevalence of incidentally detected pancreatic cystic lesions in asymptomatic individuals. Pancreatology. 2019;19:2–9.CrossRef Zerboni G, Signoretti M, Crippa S, et al. Systematic review and meta-analysis: prevalence of incidentally detected pancreatic cystic lesions in asymptomatic individuals. Pancreatology. 2019;19:2–9.CrossRef
3.
go back to reference Kromrey ML, Bulow R, Hubner J, et al. Prospective study on the incidence, prevalence and 5-year pancreatic-related mortality of pancreatic cysts in a population-based study. Gut. 2018;67:138–145.CrossRef Kromrey ML, Bulow R, Hubner J, et al. Prospective study on the incidence, prevalence and 5-year pancreatic-related mortality of pancreatic cysts in a population-based study. Gut. 2018;67:138–145.CrossRef
4.
go back to reference Tanaka M, Fernandez-Del CC, Kamisawa T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017;17:738–753.CrossRef Tanaka M, Fernandez-Del CC, Kamisawa T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017;17:738–753.CrossRef
5.
go back to reference Elta GH, Enestvedt BK, Sauer BG, et al. ACG clinical guideline: diagnosis and management of pancreatic cysts. Am J Gastroenterol. 2018;113:464–479.CrossRef Elta GH, Enestvedt BK, Sauer BG, et al. ACG clinical guideline: diagnosis and management of pancreatic cysts. Am J Gastroenterol. 2018;113:464–479.CrossRef
6.
go back to reference Marco DC, Marc GB, Lianne S, et al. European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic neoplasms. Gut. 2018;67:789–804. Marco DC, Marc GB, Lianne S, et al. European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic neoplasms. Gut. 2018;67:789–804.
7.
go back to reference Elias KM, Tsantoulis P, Tille JC, et al. Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors. J Pathol. 2018;246:459–469.CrossRef Elias KM, Tsantoulis P, Tille JC, et al. Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors. J Pathol. 2018;246:459–469.CrossRef
8.
go back to reference Ma GK, Goldberg DS, Thiruvengadam N, et al. Comparing american gastroenterological association pancreatic cyst management guidelines with Fukuoka consensus guidelines as predictors of advanced neoplasia in patients with suspected pancreatic cystic neoplasms. J Am Coll Surg. 2016;223:729–737.CrossRef Ma GK, Goldberg DS, Thiruvengadam N, et al. Comparing american gastroenterological association pancreatic cyst management guidelines with Fukuoka consensus guidelines as predictors of advanced neoplasia in patients with suspected pancreatic cystic neoplasms. J Am Coll Surg. 2016;223:729–737.CrossRef
9.
go back to reference Xu MM, Yin S, Siddiqui AA, et al. Comparison of the diagnostic accuracy of three current guidelines for the evaluation of asymptomatic pancreatic cystic neoplasms. Medicine (Baltimore). 2017;96:e7900.CrossRef Xu MM, Yin S, Siddiqui AA, et al. Comparison of the diagnostic accuracy of three current guidelines for the evaluation of asymptomatic pancreatic cystic neoplasms. Medicine (Baltimore). 2017;96:e7900.CrossRef
10.
go back to reference Lekkerkerker SJ, Besselink MG, Busch OR, et al. Comparing 3 guidelines on the management of surgically removed pancreatic cysts with regard to pathological outcome. Gastrointest Endosc. 2017;85:1025–1031.CrossRef Lekkerkerker SJ, Besselink MG, Busch OR, et al. Comparing 3 guidelines on the management of surgically removed pancreatic cysts with regard to pathological outcome. Gastrointest Endosc. 2017;85:1025–1031.CrossRef
11.
go back to reference Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology. 2006;6:17–32.CrossRef Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology. 2006;6:17–32.CrossRef
12.
go back to reference Tanaka M, Fernandez-del CC, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12:183–197.CrossRef Tanaka M, Fernandez-del CC, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12:183–197.CrossRef
13.
go back to reference Vilardaga R, Rizo J, Palenski P, et al. Pilot randomized controlled trial of a novel smoking cessation app designed for individuals with co-occurring tobacco dependence and serious mental illness. Nicotine Tob Res. 2019. https://doi.org/10.1093/ntr/ntz202. Vilardaga R, Rizo J, Palenski P, et al. Pilot randomized controlled trial of a novel smoking cessation app designed for individuals with co-occurring tobacco dependence and serious mental illness. Nicotine Tob Res. 2019. https://​doi.​org/​10.​1093/​ntr/​ntz202.
14.
go back to reference Korc M, Jeon CY, Edderkaoui M, et al. Tobacco and alcohol as risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol. 2017;31:529–536.CrossRef Korc M, Jeon CY, Edderkaoui M, et al. Tobacco and alcohol as risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol. 2017;31:529–536.CrossRef
15.
go back to reference Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008;134:95–101.CrossRef Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008;134:95–101.CrossRef
16.
go back to reference Flejou JF. WHO classification of digestive tumors: the fourth edition. Ann Pathol. 2011;31:S27–S31.CrossRef Flejou JF. WHO classification of digestive tumors: the fourth edition. Ann Pathol. 2011;31:S27–S31.CrossRef
17.
go back to reference Sainani NI, Saokar A, Deshpande V, et al. Comparative performance of MDCT and MRI with MR cholangiopancreatography in characterizing small pancreatic cysts. AJR Am J Roentgenol. 2009;193:722–731.CrossRef Sainani NI, Saokar A, Deshpande V, et al. Comparative performance of MDCT and MRI with MR cholangiopancreatography in characterizing small pancreatic cysts. AJR Am J Roentgenol. 2009;193:722–731.CrossRef
18.
go back to reference Jones MJ, Buchanan AS, Neal CP, et al. Imaging of indeterminate pancreatic cystic lesions: a systematic review. Pancreatology. 2013;13:436–442.CrossRef Jones MJ, Buchanan AS, Neal CP, et al. Imaging of indeterminate pancreatic cystic lesions: a systematic review. Pancreatology. 2013;13:436–442.CrossRef
19.
go back to reference Song SJ, Lee JM, Kim YJ, et al. Differentiation of intraductal papillary mucinous neoplasms from other pancreatic cystic masses: comparison of multirow-detector CT and MR imaging using ROC analysis. J Magn Reson Imaging. 2007;26:86–93.CrossRef Song SJ, Lee JM, Kim YJ, et al. Differentiation of intraductal papillary mucinous neoplasms from other pancreatic cystic masses: comparison of multirow-detector CT and MR imaging using ROC analysis. J Magn Reson Imaging. 2007;26:86–93.CrossRef
21.
go back to reference Stark A, Donahue TR, Reber HA, et al. Pancreatic cyst disease: a review. JAMA. 2016;315:1882–1893.CrossRef Stark A, Donahue TR, Reber HA, et al. Pancreatic cyst disease: a review. JAMA. 2016;315:1882–1893.CrossRef
22.
go back to reference Jais B, Rebours V, Malleo G, et al. Serous cystic neoplasm of the pancreas: a multinational study of 2622 patients under the auspices of the International Association of Pancreatology and European Pancreatic Club (European Study Group on Cystic Tumors of the Pancreas). Gut. 2016;65:305–312.CrossRef Jais B, Rebours V, Malleo G, et al. Serous cystic neoplasm of the pancreas: a multinational study of 2622 patients under the auspices of the International Association of Pancreatology and European Pancreatic Club (European Study Group on Cystic Tumors of the Pancreas). Gut. 2016;65:305–312.CrossRef
24.
go back to reference Maisonneuve P, Lowenfels AB. Risk factors for pancreatic cancer: a summary review of meta-analytical studies. Int J Epidemiol. 2015;44:186–198.CrossRef Maisonneuve P, Lowenfels AB. Risk factors for pancreatic cancer: a summary review of meta-analytical studies. Int J Epidemiol. 2015;44:186–198.CrossRef
25.
go back to reference Mizuno S, Isayama H, Nakai Y, et al. Prevalence of pancreatic cystic lesions is associated with diabetes mellitus and obesity: an analysis of 5296 individuals who underwent a preventive medical examination. Pancreas. 2017;46:801–805.CrossRef Mizuno S, Isayama H, Nakai Y, et al. Prevalence of pancreatic cystic lesions is associated with diabetes mellitus and obesity: an analysis of 5296 individuals who underwent a preventive medical examination. Pancreas. 2017;46:801–805.CrossRef
26.
go back to reference Konings IC, Harinck F, Poley JW, et al. Prevalence and progression of pancreatic cystic precursor lesions differ between groups at high risk of developing pancreatic cancer. Pancreas. 2017;46:28–34.CrossRef Konings IC, Harinck F, Poley JW, et al. Prevalence and progression of pancreatic cystic precursor lesions differ between groups at high risk of developing pancreatic cancer. Pancreas. 2017;46:28–34.CrossRef
27.
go back to reference Jang JY, Park T, Lee S, et al. Proposed nomogram predicting the individual risk of malignancy in the patients with branch duct type intraductal papillary mucinous neoplasms of the pancreas. Ann Surg. 2017;266:1062–1068.CrossRef Jang JY, Park T, Lee S, et al. Proposed nomogram predicting the individual risk of malignancy in the patients with branch duct type intraductal papillary mucinous neoplasms of the pancreas. Ann Surg. 2017;266:1062–1068.CrossRef
28.
go back to reference Jung W, Park T, Kim Y, et al. Validation of a nomogram to predict the risk of cancer in patients with intraductal papillary mucinous neoplasm and main duct dilatation of 10 mm or less. Br J Surg. 2019;106:1829–1836.CrossRef Jung W, Park T, Kim Y, et al. Validation of a nomogram to predict the risk of cancer in patients with intraductal papillary mucinous neoplasm and main duct dilatation of 10 mm or less. Br J Surg. 2019;106:1829–1836.CrossRef
29.
go back to reference Overbeek KA, Alblas M, Gausman V, et al. Development of a stratification tool to identify pancreatic intraductal papillary mucinous neoplasms at lowest risk of progression. Aliment Pharmacol Ther. 2019;50:789–799.CrossRef Overbeek KA, Alblas M, Gausman V, et al. Development of a stratification tool to identify pancreatic intraductal papillary mucinous neoplasms at lowest risk of progression. Aliment Pharmacol Ther. 2019;50:789–799.CrossRef
30.
go back to reference Attiyeh MA, Fernandez-Del CC, Al EM, et al. Development and validation of a multi-institutional preoperative nomogram for predicting grade of dysplasia in intraductal papillary mucinous neoplasms (IPMNs) of the pancreas: a report from the pancreatic surgery consortium. Ann Surg. 2018;267:157–163.CrossRef Attiyeh MA, Fernandez-Del CC, Al EM, et al. Development and validation of a multi-institutional preoperative nomogram for predicting grade of dysplasia in intraductal papillary mucinous neoplasms (IPMNs) of the pancreas: a report from the pancreatic surgery consortium. Ann Surg. 2018;267:157–163.CrossRef
31.
go back to reference Majumder S, Taylor WR, Yab TC, et al. Novel methylated DNA markers discriminate advanced neoplasia in pancreatic cysts: marker discovery, tissue validation, and cyst fluid testing. Am J Gastroenterol. 2019;114:1539–1549.CrossRef Majumder S, Taylor WR, Yab TC, et al. Novel methylated DNA markers discriminate advanced neoplasia in pancreatic cysts: marker discovery, tissue validation, and cyst fluid testing. Am J Gastroenterol. 2019;114:1539–1549.CrossRef
32.
go back to reference Das KK, Geng X, Brown JW, et al. Cross validation of the monoclonal antibody das-1 in identification of high-risk mucinous pancreatic cystic lesions. Gastroenterology. 2019;157:720–730.CrossRef Das KK, Geng X, Brown JW, et al. Cross validation of the monoclonal antibody das-1 in identification of high-risk mucinous pancreatic cystic lesions. Gastroenterology. 2019;157:720–730.CrossRef
33.
go back to reference Jabbar KS, Arike L, Verbeke CS, et al. Highly accurate identification of cystic precursor lesions of pancreatic cancer through targeted mass spectrometry: a phase IIc diagnostic study. J Clin Oncol. 2018;36:367–375.CrossRef Jabbar KS, Arike L, Verbeke CS, et al. Highly accurate identification of cystic precursor lesions of pancreatic cancer through targeted mass spectrometry: a phase IIc diagnostic study. J Clin Oncol. 2018;36:367–375.CrossRef
34.
go back to reference Alvarez-Sanchez MV, Napoleon B. New horizons in the endoscopic ultrasonography-based diagnosis of pancreatic cystic lesions. World J Gastroenterol. 2018;24:2853–2866.CrossRef Alvarez-Sanchez MV, Napoleon B. New horizons in the endoscopic ultrasonography-based diagnosis of pancreatic cystic lesions. World J Gastroenterol. 2018;24:2853–2866.CrossRef
35.
go back to reference Krishna SG, Hart PA, Malli A, et al. Endoscopic ultrasound-guided confocal laser endomicroscopy increases accuracy of differentiation of pancreatic cystic lesions. Clin Gastroenterol Hepatol. 2019;18:432–440.CrossRef Krishna SG, Hart PA, Malli A, et al. Endoscopic ultrasound-guided confocal laser endomicroscopy increases accuracy of differentiation of pancreatic cystic lesions. Clin Gastroenterol Hepatol. 2019;18:432–440.CrossRef
36.
go back to reference Crino SF, Bernardoni L, Brozzi L, et al. Association between macroscopically visible tissue samples and diagnostic accuracy of EUS-guided through-the-needle microforceps biopsy sampling of pancreatic cystic lesions. Gastrointest Endosc. 2019;90:933–943.CrossRef Crino SF, Bernardoni L, Brozzi L, et al. Association between macroscopically visible tissue samples and diagnostic accuracy of EUS-guided through-the-needle microforceps biopsy sampling of pancreatic cystic lesions. Gastrointest Endosc. 2019;90:933–943.CrossRef
Metadata
Title
High-Risk Characteristics Associated with Advanced Pancreatic Cystic Lesions: Results from a Retrospective Surgical Cohort
Authors
Liqi Sun
Wei Wang
Huiyun Zhu
Fei Jiang
Lisi Peng
Gang Jin
Zhendong Jin
Publication date
01-06-2021
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 6/2021
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-020-06481-2

Other articles of this Issue 6/2021

Digestive Diseases and Sciences 6/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.